SER · Serina Therapeutics, Inc. · Proposed Sales
$1.75
+0.11 (+6.71%)
At close · Oct 29
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that our existing cash and cash equivalents are not expected to be sufficient to fund our operations for the 12 months following the issuance of our unaudited condensed consolidated financial statements for the period ended June 30, 2026, and that substantial doubt about our ability to continue as a going concern continues to exist.”View the 10-Q filed Aug 13, 2026
Market Cap
$44.45M
Shares
25.40M
Volume · Oct 29
20.14K
Avg daily vol (3M)
66.26K
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-01-20 | Moreadith Randall | Officer | 91,000 | 2026-01-20 | Stifel Nicolaus & Company Inc |
| 2025-10-14 | Moreadith Randall | Officer | 88,826 | 2025-10-13 | Stifel Nicolaus & Company Inc |
| 2025-06-30 | Moreadith Randall | Officer | 99,674 | 2025-06-30 | Stifel Nicolaus & Company Inc |
Showing 1–3 of 3 filings